Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572395 | 0.91 | HCAR3 (0.39) | MMP3NPC1RAB9ASMN1; SMN2HCAR3 | |
| SCHEMBL6929213 | 0.82 | MMP2 (0.40) | MMP2MMP9MMP3PTGS2NPC1 | |
| SCHEMBL7987626 | 0.81 | ACACB (0.35) | MMP2MCL1MMP13MAPTADAMTS4 | |
| SCHEMBL7983353 | 0.73 | CHRNA1 (0.42) | MMP2MMP9MMP3SLC6A2PTGS2 | |
| SCHEMBL6932927 | 0.73 | CHRNA1 (0.42) | MMP2MMP9MMP3SLC6A2PTGS2 | |
| SCHEMBL7984718 | 0.73 | CHRNA1 (0.42) | MMP2MMP9MMP3SLC6A2PTGS2 | |
| SCHEMBL6026229 | 0.69 | ADK (0.39) | ATMMAPT | |
| SCHEMBL6026268 | 0.67 | CFTR (0.39) | MMP2MMP9MMP3NPC1RAB9A | |
| SCHEMBL6934106 | 0.67 | PTGS2 (0.39) | PTGS2RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6026464 | 0.67 | EGFR (0.43) | MMP2MMP9MMP3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246811-B1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6613919-B2 | Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones | OXIS ISLE OF MAN | 2003-09-02 | — | — | US | disclosed |
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | OXIS ISLE OF MAN | 2003-04-03 | — | — | US | disclosed |
| EP-1246811-A1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS Isle of Man, Limited (GB) | 2002-10-09 | — | — | EP | disclosed |
| US-6262073-B1 | INHIBITING THE ACTION OF A PRO-INFLAMMATORY CYTOKINE | OXIS INTERNATIONAL INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2001049671-A1 | METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES | OXIS ISLE OF MAN, LIMITED (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6136832-A | RACEMIC MIXTURES AND ENANTIOMORPHS | OXIS INTERNATIONAL INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-6005000-A | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor | OXIS INTERNATIONAL, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0938482-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | Oxis International, Inc. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007714-A1 | 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR | OXIS INTERNATIONAL, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065196-A1 | Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones | ADH1C, SRD5A2, SRD5A1 | MMP2 812/4885MMP9 559/4885MMP3 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.